There are continued debates on potential proarrhythmic effects of intracoronary bone marrow-derived progenitor cell (BMC) therapy for treatment of chronic heart failure. Implantable cardioverter-defibrillators (ICDs), a mainstay of heart failure therapy, provide the possibility of validly assessing arrhythmias in patients with chronic heart failure. The aim of this analysis was to assess the arrhythmogenic potential of intracoronary BMC therapy, continuously documented by ICD-stored intracardiac electrograms.
Introduction
Cell therapy has emerged as a promising possibility to treat patients with acute myocardial infarction 1, 2 or chronic heart failure. 3, 4 The majority of clinical studies examining the effects of cell therapy demonstrated a modest benefit on improvement of cardiac function. 5 However, there are continued debates on potential proarrhythmic effects of cardiac cell therapy. 6 -8 The early clinical experience with intramyocardial injection of skeletal myoblasts, which remain electrically isolated after engraftment due to insufficient gap junction formation with the host tissue, 9 disclosed a clinically significant proarrhythmic effect, which led to the mandatory use of automatic implanted cardioverter-defibrillators (ICDs) in subsequent trials. 10 -12 Similarly, the intramyocardial injection of bone marrow-derived mononuclear cells (BMC) has been linked, albeit to a lesser degree, to enhanced ventricular arrhythmogenicity in a small series of 20 patients. 13 In contrast, recent meta-analyses summarizing the clinical outcome of intracoronary administration of BMC did not point towards an increased arrhythmic risk. 14 Of note, most trials used only the standard electrocardiogram (ECG) or 24 h Holter monitoring to assess arrhythmic events during follow-up; this methodology, however, is insufficiently accurate to detect serious and potentially lifethreatening arrhythmic events. Hence, to disclose potential arrhythmic consequences of intracoronary administration of BMC in patients with chronic heart failure fitted with an ICD, ICD-stored episodes of ventricular tachycardia (VT) or fibrillation (VF) were examined in a large cohort of patients over a follow-up period of 2 years.
Materials and methods

Study population
In the present matched cohort study, a total of 336 patients with chronic heart failure fitted with an ICD were studied. Of these patients, 112 received intracoronary administration of autologous BMC at our institution within an observational registry study (clinicaltrials.gov-ID: NCT00962364) or within the TOPCARE-DCM trial 15 (clinicaltrials.gov-ID: NCT00284714) between 2002 and 2008.
A group of 224 heart failure patients, matched for age, gender, and left ventricular ejection fraction (LVEF), served as a control group. These patients were recruited from a database of heart failure patients with ICD therapy, who had received an ICD device between 1997 and 2007. 16 Subjects from the control group were included into the analysis on the date of ICD implantation, whereas subjects from the BMC therapy group were included at the date of intracoronary progenitor cell administration.
Implantable cardioverter-defibrillator recordings and analysis
The ICD-stored intracardiac electrograms (EGM) were interrogated at three follow-up dates after 4 -6 months, after 12 months, and after 2 years, respectively. Arrhythmic endpoints were episodes of sustained VT or VF treated either by antitachycardia pacing (ATP) or ICD shock. The exact timing of arrhythmic events as assessed by EGM analysis was available in 96 patients (85.7%) of the BMC group and in 199 patients (88.8%) of the control group. Any ICD therapy not delivered for VT or VF was deemed inappropriate and recorded separately. Implantable cardioverter-defibrillator programming was individualized according to each patient's needs, contemporary guidelines, and device properties. In addition, EGM-documented new episodes of atrial fibrillation were documented in patients with a dual-or triple-chamber ICD, whereas in the group of patients with a single-chamber ICD surface, ECGs were analysed with regard to atrial fibrillation at the follow-up dates. State of health, medical history, and potential causes of death were obtained by careful review of hospital records. Causes of death were classified according to a modified Hinkle and Thaler classification scheme, 17 which has been validated in several arrhythmia 18, 19 and ICD 20 -22 studies.
Calculation of Seattle Heart Failure Model-predicted mortality 
Results
The baseline characteristics of the study cohort are described in Table 1 . According to the matching criteria used, patients with BMC treatment did not differ with respect to age, gender, or LVEF from patients of the control group. The mean duration of heart failure was significantly longer (P ¼ 0.001) in the BMC-treated group with 103.9 + 86.7 (median: 84.0) months compared with the control group with a mean duration of heart failure of 86.2 + 99.6 (median: 46.5) months. Moreover, the predicted survival, as determined by the SHFM, 23 was significantly lower (P ¼ 0.006) in patients undergoing intracoronary BMC administration compared with the control group. Implantable cardioverter-defibrillator type, indication for ICD implantation, QRS duration analysed via surface ECG, and pharmacological antiarrhythmic and heart failure therapy as well as arrhythmic events before inclusion into the analysis did not differ significantly between the two groups. Total patientyears at risk were 595 years. Table 2 summarizes the incidence and the time to the first arrhythmic event during the follow-up. The exact time to first arrhythmic event was available in 96 patients of the BMC group and in 199 patients of the control group. No significant difference between the two groups was detected for any of the tested endpoints. In the BMC-treated group, analysis of the ICD-stored intracardiac EGM revealed VT in 25% of the patients occurring 612 + 234 days after BMC therapy during the 2-year follow-up period after cell therapy. In the control group, VT occurred in 27% of the patients 598 + 242 days after inclusion into the analysis. atrial fibrillation in the two analysed study cohorts. Similar results were observed when stratifying the patients into ischaemic vs. nonischaemic causes of heart failure (data not shown). Moreover, in a subgroup of 43 patients, who had intracardiac EGM analysis at our institution in the 4 months preceding BMC administration as well as during 4 months following BMC administration, the incidence of ICD-stored VT or VF was 11.6% prior to compared with 7.0% following BMC administration (P ¼ 0.73). Thus, using BMC-treated patients as their own control did not reveal an increased incidence of VT/VF after BMC therapy. Logistic regression analysis of different clinical and electrophysiological variables regarding the occurrence of a combined endpoint of arrhythmic morbidity and mortality demonstrated that male gender, increased severity of heart failure as assessed by New York Heart Association (NYHA) classification, LVEF ≤30%, low systolic blood pressure, a prolonged QRS duration ≥120 ms, renal failure, and implantation of the ICD as a measure of secondary prevention were significant multivariate predictors of an increased incidence of arrhythmias. In contrast, there was no association between the intracoronary administration of BMC and the combined endpoint of ICD-treated arrhythmias and arrhythmic death ( 
Discussion
The results of the present study demonstrate that intracoronary administration of BMC was not associated with a subsequently increased risk for arrhythmic events in patients with chronic heart failure. During a total time of 595 patient-years at risk, the incidence of VT or VF as well as of new onset atrial fibrillation did not differ between patients receiving intracoronary BMC administration and a matched control group.
The presence of an ICD allows for continuous surveillance of arrhythmic events in patients with chronic heart failure. Interrogation of ICD-stored arrhythmic events revealed that VT in 25% of the patients receiving intracoronary BMC administration and in 27% of the control patients during the 2-year follow-up period. In addition, 5.2% of the patients receiving intracoronary BMC administration vs. 6.5% of the control patients suffered from VF. Thus, the patient cohort of the present study indeed comprises patients with chronic heart failure at a moderate-to-high risk for life-threatening arrhythmic events with a yearly incidence of 7%, comparable with the SCD-HeFT study population. 26 However, neither early after cell administration nor throughout the 2-year follow-up period was there any evidence of an increased risk for VT or VF in the cell-treated group of patients, whereas the well-established predictors for life-threatening arrhythmias in patients with chronic heart failure, such as male gender, NYHA classification, lower ejection fraction, and implantation of an ICD for secondary prevention predicted the occurrence of arrhythmic events. Importantly, although patients were matched for age, gender, and LVEF, as the latter has been shown to be associated with ICD interactions, 27 the patients receiving intracoronary BMC had a significantly lower SHFM-predicted survival compared with the control patients. Thus, given that the SHFM has been shown to be a potent predictor of death in patients receiving ICD therapy, 28 the comparable incidence of ventricular arrhythmic events in both groups is reassuring that intracoronary BMC administration does not aggravate ventricular tachyarrhythmias in patients with chronic heart failure. A potential proarrhythmic effect of cardiac cell therapy has been mainly attributed to the lack of applied cells to electrically couple with the surrounding cardiac myocytes, leading to potentially enhanced automaticity or setting the stage for re-entry. 6 Indeed, when BMC were experimentally injected into the ischaemic regions of the myocardium, they were located in clusters within the infarct border zone without showing any electrical coupling and absence of gap junctions, 29 thus causing heterogeneity in conduction and increased ventricular premature complexes for 28 days post-injection. 30 However, when BMC were applied via the intracoronary route of administration, ventricular premature complex occurrence was markedly decreased, suggesting a more homogeneous delivery of cells. 30 Clinical proof-of-concept studies demonstrated that 2-5% of the administered BMC are acutely retained in the heart after intracoronary infusion in patients with chronic heart failure. 31 It is currently assumed that potential beneficial effects of intracoronary BMC administration on cardiac function are mediated by the release of paracrine factors from the retained cells to enhance endogenous repair mechanisms and improve the function of the coronary microcirculation. 15, 32, 33 The results of the present study demonstrating an absence of arrhythmic effects after intracoronary BMC administration indeed supports a paracrine mechanism of BMC therapy rather than the persistence of the applied cells with potentially enhanced automaticity due to failure of electrical coupling.
Limitations of the study
Although the present study comprises by far the largest cohort of patients treated with BMC for chronic heart failure, there are several potential limitations of the present analysis. First, the sample size of the study population is rather small as evidenced by a type II error of 9.6% for the statistical analysis. However, statistical modeling revealed that the sample size is sufficient to ascertain that the difference in the occurrence of the composite endpoint is less than 5%, which appears to be clinically reasonable. Second, the observation period was limited to 2 years of follow-up after intracoronary BMC administration. However, we do believe that any potential arrhythmic events secondary to the administration of BMC should have occurred within this time span. Third, this is a non-randomized matched cohort study with all potential limitations of such a design. In addition, the 2-year follow-up observation period started at the time of BMC administration in the cell treated group, but at the time of ICD implantation in the control group, which might have introduced some bias into the study. Nevertheless, analysis of a subgroup of patients, in whom intracardiac EGM could be recorded in the 4 months preceding BMC administration as well as during the 4 months following BMC administration, did not reveal any increase in the incidence of VT/VF after cell therapy. Also, the detection of atrial fibrillation by surface ECG in the group of patients with a single-chamber ICD is not as reliable as analysing EGMdocumented episodes of atrial fibrillation in dual-and triple-chamber ICDs, but the percentage of patients with a single-chamber ICD did not significantly differ between the two study groups. In summary, the results of the present study suggest that there is no evidence that BMC administered via the intracoronary route does provide a proarrhythmic substrate in patients with chronic heart failure. The documentation of a lack of an increased risk of life-threatening arrhythmias confirms the results of previous meta-analyses, demonstrating a modest, but measureable improvement in the clinical outcome in patients treated for chronic heart failure by intracoronary administration of autologous BMC. 14, 34 
